Health officials admit fast tracked shots could cause deaths
Monday, August 10, 2009
Government health officials in the Czech Republic have refused to buy H1N1 flu vaccines from US pharmaceutical firm Baxter International, citing safety concerns.
According to a report by the Czech News Agency CTK, one of the largest English language news outlets in the country, the Czech Health Ministry has halted talks with Baxter citing “the firm’s inability to guarantee that the vaccine is safe and who will bear the risks for possible side-effects.”
The country plans to buy vaccines to cover 25 percent of its population of ten million, but has said it will not buy swine flu vaccine from Baxter before it has acquired a European registration.
“It is a pity, but, unfortunately, at the moment when we accepted the bids, Baxter was unable to confirm that it will deliver a registered vaccine,” Health Minister Dana Juraskova said.
Instead, the country will likely buy its supplies from Novartis and GlaxoSmithKline, but only after the vaccines have undergone regular clinical tests and gained European Medicines Agency registration.
In another CTK report, Deputy Health minister Marek Snajdr was quoted as saying the vaccine “may have side effects and it may even cause death if used”.
Confirmed cases of H1N1 flu in the country remain below 150, according to all estimates, and no one has died from the virus.
(Article continues below)
As we have previously noted, Baxter has a very recent and most disturbing connection to flu vaccines and the Czech Republic.
As reported by multiple sources last March, including the Times of India, vaccines contaminated with deadly live H5N1 avian flu virus were distributed to 18 countries in December 2008 by a lab at an Austrian branch of Baxter.
It was only by providence that the batch was first tested on ferrets in the Czech Republic, before being shipped out for injection into humans. The ferrets all died and the shocking discovery was made.
Czech newspapers immediately questioned whether the events were part of a conspiracy to deliberately provoke a pandemic, following up on accusations already made by health officials in other countries.
Initially, Baxter attempted to stonewall questions by invoking “trade secrets” and refused to reveal how the vaccines were contaminated with H5N1. After increased pressure they then claimed that pure H5N1 batches were sent by accident.
Since the probability of mixing a live virus biological weapon with vaccine material by accident is virtually impossible, this leaves no other explanation than that the contamination was a deliberate attempt to weaponize the H5N1 virus to its most potent extreme and distribute it via conventional flu vaccines to the population who would then infect others to a devastating degree as the disease went airborne.
The fact that Baxter mixed the deadly H5N1 virus with a mix of H3N2 seasonal flu viruses is the smoking gun. The H5N1 virus on its own has killed hundreds of people, but it is less airborne and more restricted in the ease with which it can spread. However, when combined with seasonal flu viruses, which as everyone knows are super-airborne and easily spread, the effect is a potent, super-airbone, super deadly biological weapon.
Indeed, some have already suggested that the current swine flu scare could represent the use of such a weapon.
In a separate case, an ongoing lawsuit has charged that Baxter intentionally used untested and dangerous ingredients in some of its vaccines in order to increase profits.
WHO officials are reportedly still closely monitoring ongoing investigations into Baxter’s contaminated vaccines, despite this the company is leading the way in the production of swine flu vaccines that could become mandatory. Indeed, in an well timed act of clairvoyancy, Baxter filed its swine flu vaccine patent exactly one year ahead of the outbreak.
The company announced last week that it had completed its first commercial batches of H1N1 vaccine in late July and is now in talks with national health authorities worldwide. The company has initiated a European Medicines Agency license application for the vaccine, but it has not yet been approved.
Baxter says it will provide a total of 80 million doses for 40 million people in five countries including the UK, Ireland and New Zealand.
The US will not take the Baxter-made vaccine as it has not received Food and Drug Administration approval.
In addition to regulators in Europe and the US planning to fast-track the approval of swine flu vaccines, new regulations have been put in place to provide pharmaceutical companies with blanket immunity from lawsuits.
“Vaccine makers and federal officials will be immune from lawsuits that result from any new swine flu vaccine, under a document signed by Secretary of Health and Human Services Kathleen Sebelius,” reported the Associated Press last month.
Mass vaccination will probably start at the end of November and in early December. Early reports indicate that health officials in the UK and the US are planning to set up clinics within every school in both countries.
This article was posted: Monday, August 10, 2009 at 9:25 am